enfuvirtide inn sold brand name fuzeon hiv fusion inhibitor first class antiretroviral drugs used combination therapy treatment aidshiv enfuvirtide indicated treatment infection combination therapy antiretrovirals people treatments common adverse drug reactions patients associated enfuvirtide therapy include injection site reactions pain hardening skin erythema nodules cysts itch experienced nearly patients particularly first week peripheral neuropathy insomnia depression cough dyspnoea anorexia arthralgia infections including bacterial pneumonia andor eosinophilia various hypersensitivity reactions occur infrequently patients symptoms include rash fever nausea vomiting chills rigors hypotension elevated hepatic transaminases possibly severe reactions including respiratory distress glomerulonephritis andor anaphylaxis rechallenge enfuvirtide works disrupting molecular machinery final stage fusion target cell preventing uninfected cells becoming infected biomimetic peptide enfuvirtide designed mimic components fusion machinery displace preventing normal fusion drugs disrupt fusion virus target cell termed entry inhibitors fusion inhibitorscitation needed hiv binds host cell receptor via viral protein viral transmembrane protein undergoes conformational change assists fusion viral membrane host cell membrane enfuvirtide binds preventing creation entry pore capsid virus keeping enfuvirtide also activator chemotactic factor receptor formyl peptide receptor thereby activates phagocytes presumably cells bearing receptor see formyl peptide physiological significance activation unknowncitation needed enfuvirtide considered active low activity isolates demonstrated variable susceptibility enfuvirtide observed clinical isolates acquired resistance result mutated amino acid motif viral primary resistance however yet enfuvirtide acid peptide following enfuvirtide originated duke university researchers formed pharmaceutical company known trimeris trimeris began development enfuvirtide initially designated trimeris entered partnership hoffmannla roche complete development drug approved us food drug administration fda march first hiv fusion inhibitor new class antiretroviral drugs approved basis two studies compared effect optimized regimens antiretroviral medication without addition enfuvirtide serum viral loadcitation needed httpsenwikipediaorgwikienfuvirtide